Document is current
Any future updates will be listed below
-
Authors
Anitua, Eduardo https://orcid.org/0000-0002-8386-5303
de la Fuente, María https://orcid.org/0000-0002-6820-1517
Prado, Roberto https://orcid.org/0000-0003-4767-7206
Alkhraisat, Mohammad H. https://orcid.org/0000-0003-4422-4527
-
Funding
Funding for this research was provided by:
Department of Economic Development, Sustainability and Environment of the Basque Government (Elkartek-KK-2022/00038)
- License Information
-
More Information
Article History
Received: 21 February 2025
Accepted: 10 April 2025
First Online: 24 April 2025
Declarations
:
: The protocol for this in vitro study was approved on November 7, 2022, by the Araba University Hospital Clinical Research Ethics Committee (BTI-01-IV/22/CPL).
: N/A.
: The authors declare that E.A. is the Scientific Director of, and M.d.l.F., R.P. and M.H.A. are scientists at BTI-Biotechnology Institute I MAS D, a biomedical company that investigates the fields of regenerative medicine and PRGF-Endoret technology.
